Novo Nordisk’s popular GLP-1 drug Wegovy has secured accelerated FDA approval for metabolic dysfunction-associated steatohepatitis (MASH), addressing a condition affecting an estimated 22 million U.S. adults. The approval is based on phase III data showing improved liver scarring and resolution of MASH without worsening fibrosis. Wegovy becomes the first GLP-1 agonist authorized for MASH, entering a market alongside Madrigal’s Rezdiffra. Analysts note potential patient sub-segmentation between these therapies. This label expansion underscores the broadening application of GLP-1 drugs in metabolic diseases.